Grifols stock gains as H1 profit rises 28.7 percent
Published on 10/05/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Grifols stock closed at EUR 9.60 on BME on October 1, 2026, gaining 2.56 percent as the plasma therapies group entered the final quarter with higher first-half profit. The latest company figures show net profit of EUR 227 million, up 28.7 percent from the same period of 2025.
Profit growth leads the update
According to Grifols in its investor update dated July 28, 2026, first-half revenue rose 2.6 percent at constant currency to EUR 3.6 billion, while net profit reached EUR 227 million. The company also reported EUR 1.7 billion of revenue in the first quarter and EUR 1.9 billion in the second quarter.
The earnings mix matters because Biopharma revenue increased 5.4 percent at constant currency in the first half, ahead of group revenue growth. That comparison places the core plasma-derived therapies business above the overall group pace, although the figures use constant-currency growth rather than reported-currency growth.
Margins and cash flow improve
Quartr reported on October 1, 2026, that adjusted EBITDA reached EUR 854 million in H1 2026, up 2.4 percent year over year at constant currency, with an adjusted EBITDA margin of 23.9 percent. Full-year guidance calls for an adjusted EBITDA margin of at least 25 percent and free cash flow before acquisitions of EUR 500 million to EUR 575 million.
Free cash flow before mergers and acquisitions reached EUR 91 million in the first half, an improvement of EUR 103 million from the prior-year period. Net leverage stood at 4.2 times, making debt reduction and cash conversion important counterweights to the improving earnings trend.
Consensus target remains higher
MarketScreener lists an Outperform consensus from 12 analysts, with an average price target of EUR 14.76. The consensus target is distinct from the reported share price and reflects the combined analyst view rather than a single bank recommendation.
A separate operational risk came into view in September. Reuters reported on September 24, 2026, that Health Canada suspended the license to collect plasma at Grifols' Taylor Avenue facility in Winnipeg, while the company said ongoing operations were not affected.
Grifols stock holds at EUR 9.60
Grifols stock closed at EUR 9.60 on BME on October 1, 2026, with the 2.56 percent daily gain following the latest completed exchange session. The stock is listed under ticker GRF.MC in the health care sector and is a member of the IBEX 35.
Grifols stock key data
- Company: Grifols, S.A.
- ISIN: ES0171996087
- Ticker: GRF.MC
- Trading venue: BME
- Closing price (October 1, 2026): EUR 9.60
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: IBEX 35
